BACKGROUND: There is strong scientific evidence that human papillomavirus (HPV) vaccines, which protect against two oncogenic HPV types (16 and 18), can prevent cervical, vaginal, and vulvar cancers in women. In addition, recent research has established that the HPV vaccine can prevent anal cancer and has implied that it may also prevent oropharyngeal cancers. METHODS: A 2009 web-based survey of 1500 physicians from four specialties (pediatricians, family practitioners, internists, and obstetrician-gynecologists) explored knowledge about which female cancers the HPV vaccine was effective in preventing. Physician characteristics associated with the belief that the HPV vaccine prevents cervical, vaginal, vulvar, anal, and other cancers were examined using logistic regression models. RESULTS: Nearly all respondents (97.8%) identified cervical cancer as being prevented by the HPV vaccine; however, lower awareness that the vaccine prevents vaginal (23.8%), vulvar (27.8%), and anal cancer (28.4%) was found. Physician specialty was the most significant covariate identified, with obstetrician-gynecologists being more likely than other physicians to report that the HPV vaccine protected against vaginal (p<0.001), vulvar (p<0.001), and anal (p<0.001) cancers. CONCLUSIONS: Physicians may benefit from educational efforts clarifying which noncervical cancers can be prevented by the HPV vaccine. Education is needed across all medical specialties, but it is particularly important for pediatricians and family practitioners, the physicians most likely to administer the HPV vaccine to young adolescents.
BACKGROUND: There is strong scientific evidence that human papillomavirus (HPV) vaccines, which protect against two oncogenic HPV types (16 and 18), can prevent cervical, vaginal, and vulvar cancers in women. In addition, recent research has established that the HPV vaccine can prevent anal cancer and has implied that it may also prevent oropharyngeal cancers. METHODS: A 2009 web-based survey of 1500 physicians from four specialties (pediatricians, family practitioners, internists, and obstetrician-gynecologists) explored knowledge about which female cancers the HPV vaccine was effective in preventing. Physician characteristics associated with the belief that the HPV vaccine prevents cervical, vaginal, vulvar, anal, and other cancers were examined using logistic regression models. RESULTS: Nearly all respondents (97.8%) identified cervical cancer as being prevented by the HPV vaccine; however, lower awareness that the vaccine prevents vaginal (23.8%), vulvar (27.8%), and anal cancer (28.4%) was found. Physician specialty was the most significant covariate identified, with obstetrician-gynecologists being more likely than other physicians to report that the HPV vaccine protected against vaginal (p<0.001), vulvar (p<0.001), and anal (p<0.001) cancers. CONCLUSIONS: Physicians may benefit from educational efforts clarifying which noncervical cancers can be prevented by the HPV vaccine. Education is needed across all medical specialties, but it is particularly important for pediatricians and family practitioners, the physicians most likely to administer the HPV vaccine to young adolescents.
Authors: Joel M Palefsky; Anna R Giuliano; Stephen Goldstone; Edson D Moreira; Carlos Aranda; Heiko Jessen; Richard Hillman; Daron Ferris; Francois Coutlee; Mark H Stoler; J Brooke Marshall; David Radley; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: A Blythe Ryerson; Edward S Peters; Steven S Coughlin; Vivien W Chen; Maura L Gillison; Marsha E Reichman; Xiaocheng Wu; Anil K Chaturvedi; Kelly Kawaoka Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Alfred Saah; Eliav Barr; Richard M Haupt Journal: Cancer Prev Res (Phila) Date: 2009-09-29
Authors: Abbey B Berenson; Mahbubur Rahman; Jacqueline M Hirth; Richard E Rupp; Kwabena O Sarpong Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Ashlyn Tom; Hali Robinett; Lee Buenconsejo-Lum; Reni Soon; Michael Hamilton; Pia Francisco-Natanauan; May Rose Dela Cruz; Ronald Balajadia; Brenda Y Hernandez Journal: J Community Health Date: 2016-10
Authors: Lisa A McSherry; Eamonn O'Leary; Stephan U Dombrowski; Jill J Francis; Cara M Martin; John J O'Leary; Linda Sharp Journal: PLoS One Date: 2018-12-13 Impact factor: 3.240
Authors: Kathleen B Cartmell; Jennifer Young-Pierce; Shannon McGue; Anthony J Alberg; John S Luque; Maria Zubizarreta; Heather M Brandt Journal: Papillomavirus Res Date: 2017-12-07